Immunohistochemistry analysis of GLUT-1 showing staining in the cytoplasm of paraffin-embedded human pancreas tissue (right) compared to a negative control without primary antibody (left). To expose target proteins, antigen retrieval was performed using 10mM sodium citrate (pH 6.0), microwaved for 8-15 min. Following antigen retrieval, tissues were blocked in 3% H2O2-methanol for 15 min at room temperature, washed with ddH2O and PBS, and then probed with a GLUT-1 Mouse Monoclonal Antibody (MA511315) diluted in 3% BSA-PBS at a dilution of 1:20 for 1 hour at 37°C in a humidified chamber. Tissues were washed extensively in PBST and detection was performed using an HRP-conjugated secondary antibody followed by colorimetric detection using a DAB kit. Tissues were counterstained with hematoxylin and dehydrated with ethanol and xylene to prep for mounting.
|Tested species reactivity||Human, Mouse, Rat|
|Published species reactivity||Human|
|Host / Isotype||Mouse / IgG2a, kappa|
|Immunogen||A synthetic peptide derived from C-terminal of human GLUT-1|
|Storage buffer||PBS, pH 7.6, with 0.2% BSA|
|Contains||15mM sodium azide|
|Storage Conditions||4° C|
|Tested Applications||Dilution *|
|Flow Cytometry (Flow)||3-5 µg/10^6 cells|
|Immunohistochemistry (Paraffin) (IHC (P))||1:20|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
MA5-11315 targets GLUT-1 in IHC (P) applications and shows reactivity with Human and Rat samples.
The MA5-11315 immunogen is a synthetic peptide derived from C-terminal of human GLUT-1.
Glucose is fundamental to the metabolism in mammalian cells. Several glucose transporter protein (Glut) isoforms have been identified and shown to function in response to insulin and IGF-1 induced signaling. GLUT-1 is detectable in many human tissues including those of the colon, lung, stomach, esophagus, and breast. GLUT-1 immunoreactivity in some cancers, including trans carcinoma of the urinary bladder, has been associated with aggressive behavior.
IP-MS enrichment of GLUT1 (LFQ intensity): GLUT1 was enriched 339-fold from LNCAP lysate compared to background proteins, using the optimized IP-MS workflow with Pierce MS-Compatible Magnetic IP Kit protein A/G (Part No. 90409) and GLUT1 antibody (Part No. MA5-11315). The STRING database (www.string-db.org) was used to identify the protein interactor list. See more information on IP-MS verification of antibody selectivity. IP-MS validation info.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Differentiation and characterization of human pluripotent stem cell-derived brain microvascular endothelial cells.
MA5-11315 was used in immunocytochemistry to describe methods to differentiate and characterize hPSC-derived brain microvascular endothelial cells
|Stebbins MJ,Wilson HK,Canfield SG,Qian T,Palecek SP,Shusta EV||Methods (San Diego, Calif.) (101:93)||2016|
Initial Experience With Gallium-68 DOTA-Octreotate PET/CT and Peptide Receptor Radionuclide Therapy for Pediatric Patients With Refractory Metastatic Neuroblastoma.
MA5-11315 was used in immunohistochemistry - paraffin section to discuss the use of a theranostic combination to treat pediatric patients with refractory neuroblastoma
|Kong G,Hofman MS,Murray WK,Wilson S,Wood P,Downie P,Super L,Hogg A,Eu P,Hicks RJ||Journal of pediatric hematology/oncology (38:87)||2016|
HIF-1¿ and CA-IX as predictors of locoregional control for determining the optimal treatment modality for early-stage laryngeal carcinoma.
MA5-11315 was used in immunohistochemistry to study the value of the immunohistochemical expression of HIF-1alpha and carbonic anhydrase IX for selecting the optimal treatment strategy in patients with early-stage laryngeal carcinoma
|Kwon OJ,Park JJ,Ko GH,Seo JH,Jeong BK,Kang KM,Woo SH,Kim JP,Hwa JS,Carey TE||Head and neck (37:505)||2015|
High-risk human papillomavirus load and biomarkers in cervical intraepithelial neoplasia and cancer.
MA5-11315 was used in immunohistochemistry to study the relationships between high risk HPV load, the expression of various biomarkers, and cervical intraepithelial neoplasia and cancer
|Chang MS,Oh S,Jung EJ,Park JH,Jeon HW,Lee TS,Kim JH,Choi E,Byeon SJ,Park IA||APMIS : acta pathologica, microbiologica, et immunologica Scandinavica (122:427)||2014|
High FDG activity in focal fat necrosis: a pitfall in interpretation of posttreatment PET/CT in patients with non-Hodgkin lymphoma.
MA5-11315 was used in immunohistochemistry to study the ability of focal fat necrosis to confound interpretation of PET/CT data in non-Hodgkin lymphoma patients
|Kashyap R,Lau E,George A,Seymour JF,Lade S,Hicks RJ,Hofman MS||European journal of nuclear medicine and molecular imaging (40:1330)||2013|
Prognostic assessment of hypoxia and metabolic markers in cervical cancer using automated digital image analysis of immunohistochemistry.
MA5-11315 was used in immunohistochemistry to study the prognostic value of automated image analysis of the immunohistochemical expression of hypoxic and metabolic markers in cervical cancer patients
|Kim BW,Cho H,Chung JY,Conway C,Ylaya K,Kim JH,Hewitt SM||Journal of translational medicine (11:null)||2013|
Tenascin-C, GLUT-1, and syndecan-2 expression in juvenile nasopharyngeal angiofibroma: correlations to vessel density and tumor stage.
MA5-11315 was used in immunohistochemistry to study the expression of tenascin-C, Glut-1 and syndecan-2 in juvenile nasopharyngeal angiofibroma and their potential role in angiogenesis and growth
|Renkonen S,Heikkilä P,Haglund C,Mäkitie AA,Hagström J||Head and neck (35:1036)||2013|
Transforming growth factor-ß1 may be a key mediator of the fibrogenic properties of neural cells in leprosy.
MA5-11315 was used in immunohistochemistry to study the role of TGF-beta1 in driving Schwann cell phenotypic reprogramming and fibrogenesis in response to Mycobacterium leprae
|Petito RB,Amadeu TP,Pascarelli BM,Jardim MR,Vital RT,Antunes SL,Sarno EN||Journal of neuropathology and experimental neurology (72:351)||2013|
IMP3 and GLUT-1 immunohistochemistry for distinguishing benign from malignant mesothelial proliferations.
MA5-11315 was used in immunohistochemistry to study the diagnostic value of IMP3 and Glut1 in benign and malignant mesothelial proliferations
|Lee AF,Gown AM,Churg A||The American journal of surgical pathology (37:421)||2013|
Neuropilin-2 and vascular endothelial growth factor receptor-3 are up-regulated in human vascular malformations.
MA5-11315 was used in immunohistochemistry to study the expression of different VEGF isoforms and their receptors in 33 human vascular anomalies
|Partanen TA,Vuola P,Jauhiainen S,Lohi J,Salminen P,Pitkäranta A,Häkkinen SK,Honkonen K,Alitalo K,Ylä-Herttuala S||Angiogenesis (16:137)||2013|
Down-regulation of MutS homolog 3 by hypoxia in human colorectal cancer.
MA5-11315 was used in immunohistochemistry to study the role of HIF1-alpha in the mechanism by which human colon cancer MSH3 is downregulated in response to hypoxia
|Li J,Koike J,Kugoh H,Arita M,Ohhira T,Kikuchi Y,Funahashi K,Takamatsu K,Boland CR,Koi M,Hemmi H||Biochimica et biophysica acta (1823:889)||2012|
Carcinoma ex pleomorphic adenoma of the salivary glands: distinct clinicopathologic features and immunoprofiles between subgroups according to cellular differentiation.
MA5-11315 was used in immunohistochemistry to study the clinicopathological implications and mechanisms of cellular differentiation in carcinoma ex pleomorphic adenoma
|Kim JW,Kwon GY,Roh JL,Choi SH,Nam SY,Kim SY,Cho KJ||Journal of Korean medical science (26:1277)||2011|
¿B-crystallin: a novel regulator of breast cancer metastasis to the brain.
MA5-11315 was used in immunocytochemistry to study the role of alphaB-crystallin in modulating triple-negative breast cancer brain metastasis
|Malin D,Strekalova E,Petrovic V,Deal AM,Al Ahmad A,Adamo B,Miller CR,Ugolkov A,Livasy C,Fritchie K,Hamilton E,Blackwell K,Geradts J,Ewend M,Carey L,Shusta EV,Anders CK,Cryns VL||Clinical cancer research : an official journal of the American Association for Cancer Research (20:56)||2014|